Finance

Lists
Why is HURA down ७.२३%?
Dive Deeper
HURA:NASDAQ
TuHURA Biosciences Inc
US$ १.५४
-७.२३%
(-०.१२) 1D
नोभेम्बर १०, १३:५८:४३ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HURA...
Open
US$ १.६८
High
US$ १.६८
Low
US$ १.५१
Mkt. cap
९.८१ करोड
Avg. vol.
३.८२ लाख
Volume
३.६८ लाख
52-wk high
US$ ३.४१
52-wk low
US$ ०.४१
EPS
-US$ ०.५४
Beta
-०.२३
Shares outstanding
६.३७ करोड
No. of employees
२२
Open
US$ १.६८
High
US$ १.६८
Low
US$ १.५१
Mkt. cap
९.८१ करोड
Avg. vol.
३.८२ लाख
Volume
३.६८ लाख
52-wk high
US$ ३.४१
52-wk low
US$ ०.४१
EPS
-US$ ०.५४
Beta
-०.२३
Shares outstanding
६.३७ करोड
No. of employees
२२
News stories
From web sources and news partners
FinancialContent
FinancialContent
·
१ घण्टा पहिले
Utz (NYSE:UTZ) reports sales below analyst estimates in Q3 2026 earnings
The Motley Fool
The Motley Fool
·
२१ मिनेट पहिले
The Stock Market Is Shaky Right Now. Here's Why I'm Not Worried.
Seeking Alpha
Seeking Alpha
·
१७ मिनेट पहिले
UBS reaffirms its 2027 S&P 500 year-end call of 8,900
About TuHURA Biosciences Inc
CEO-
Employees२२
Founded१९९५
Headquartersताम्पा, फ्लोरिडा, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Analyst ratings
Based on 2 analysts giving stock ratings to HURA in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for HURA in the last 3 months.
Highest
Current US$ १.५४
US$ १०.०० (+५४९.३५%)
Average
US$ ९.०० (+४८४.४२%)
Lowest
US$ ८.०० (+४१९.४८%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ १०.००
+५४९.४%
10/27/2026
Jason McCarthy
Maxim Group
Buy
Maintained
US$ ८.००
+४१९.५%
08/25/2026
Silvan Turkcan
Citizens JMP
Buy
Initiated
US$ ९.००
+४८४.४%
04/27/2026
Unknown Analyst
Citizens JMP
Buy
Initiated
US$ ९.००
+४८४.४%
04/27/2026
Michael King
Rodman & Renshaw
Buy
Initiated
US$ ७.००
+३५४.५%
04/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
४९.६९ लाख
६०.५५ लाख
५२.३३ लाख
६६.२० लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१७.६१ लाख
२३.३८ लाख
२२.९७ लाख
२१.४३ लाख
Operating expense
६७.३० लाख
८३.९४ लाख
७५.३० लाख
८७.६३ लाख
Total operating expenses
६७.३० लाख
८३.९४ लाख
७५.३० लाख
८७.६३ लाख
Operating income
-६७.३० लाख
-८३.९४ लाख
-७५.३० लाख
-८७.६३ लाख
Other non operating income
-४६.७२ हजार
१.८५ लाख
-
-
EBT including unusual items
-७१.०२ लाख
-६७.६१ लाख
-७५.३७ लाख
-९२.२३ लाख
EBT excluding unusual items
-६७.८७ लाख
-८८.१७ लाख
-७५.३७ लाख
-९२.२३ लाख
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-७१.०२ लाख
-६७.६१ लाख
-७५.३७ लाख
-९२.२३ लाख
Net profit margin
-
-
-
-
Earnings per share
-०.१४
-०.१६
-०.१३
-
Interest and investment income
६.०६ हजार
६०९.००
२१.२८ हजार
७.६२ हजार
Interest expense
-१६.५३ हजार
-६.०९ लाख
-२७.९७ हजार
-४.६८ लाख
Net interest expenses
-१०.४७ हजार
-६.०८ लाख
-६.७० हजार
-४.६० लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-६७.०८ लाख
-८३.७१ लाख
-७५.०६ लाख
-८७.३५ लाख
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू